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ABSTRACT
Background mHealth applications (apps) for addictive behaviours offer widespread provision of digital support, with
particular benefits for stigmatized groups and those with poor access to treatment services. Regulation and accreditation
may encourage the uptake and use of evidence-based addictive behaviour apps, yet this is a complex and confusing land-
scape. We navigate international regulatory and accreditation guidance, explore some of the implementation challenges
and provide implications for app developers, health-care professionals and app users.Analysis We explore the classifica-
tion of health and wellbeing, blended support and clinical therapy apps as medical devices by country to help readers
navigate the complexity of the guidance. We describe an addictive behaviour app classified as a medical device and explore
the innovative approaches to regulation that are currently emerging. We discuss the use of curated on-line app libraries
that adhere to thresholds for characteristics such as quality, user satisfaction or effectiveness, which we hope will become
the starting-point in the search for suitable apps, rather than commercial app stores. We also explore the ethical concerns
associated with apps and how curated libraries address these. Conclusions International regulation of applications as
medical devices varies across countries andwould benefit from standardization in a simple, usable and transparent format.
Efforts to provide accreditation of non-medical device applications are also variable, and public bodies provide mixed mes-
sages concerning endorsement. Health-care professionals and users are encouraged to use accredited applications for ad-
dictive behaviours where they exist, or explore other forms of digital intervention with a stronger evidence base.
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INTRODUCTION
mHealth applications (apps), defined as medical and public
health practice supported by mobile devices [1], are often
hailed as a scalable approach to delivering screeningand in-
tervention for addictive behaviours. Their scalability comes
from their reach; approximatelyone-third of the global pop-
ulation has access to a smartphone (2.5 billion people in
2019 [2]), and in the United States almost 60% of people
use their smartphones to access health apps [3]. More than
325 000 health and wellbeing apps have been developed
[4], and nearly one-third of disease-specific apps have a
mental health focus, which include addictive behaviours
[5]. As such, there is potential for widespread provision of
digital support, with particular benefits for stigmatized
groups and those with poor access to treatment services.
Apps for addictive behaviours cover the spectrum of
severity, from stand-alone self-monitoring apps to adjuncts
to pharmacological treatment and fully independent ther-
apy, such as computerized cognitive behavioural therapy
(cCBT) and relapse prevention. There is a small yet emerg-
ing evidence-base for apps to reduce alcohol consumption
[6], promote smoking cessation [7–9] and prevent relapse
to illicit drugs [10–12]. However, the most popular apps
are those without effectiveness data; only two of the top
50 ranked smoking cessation apps identified in one study
had any evidence of effectiveness [13]. Furthermore,
profit-making apps that promote addictive behaviours also
benefit from access to this mass market of consumers. This
‘free ride’ may be challenged by regulation and accredita-
tion that encourages use of effective clinical innovations
—a recognized implementation strategy to promote uptake
and sustained use [14]. However, the regulation and ac-
creditation of apps is complex and, at times, confusing.
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The COVID-19 pandemic has accelerated the adoption
and normalization of digital technologies by health services
throughout the world at an unprecedented pace [15].
Without clear guidance on which apps are of high quality,
effective and safe to use, patients are at risk of substituting
effective therapeutic approaches for an app that does not
support behaviour change, puts their privacy at risk and
may ultimately result in the development of a problem or
relapse to an addictive behaviour.
This opinion piece aims to navigate two strategies that
can influence the uptake and use of evidence-based addic-
tive behaviour (i.e. smoking, alcohol consumption and il-
licit drug use) apps: (1) classifying an app as a medical
device and (2) receiving accreditation of an app by a public
body [e.g. National Health Service (NHS)]. We explore
some of the implementation challenges of this approach
and provide implications for app developers, researchers,
health-care professionals, patients and the public.
Apps as medical devices
A medical device undergoes a rigorous assessment process
to determine its quality, effectiveness and safety. The classi-
fication of an app as a medical device in principle awards it
a definitive stamp of approval, enabling health profes-
sionals to refer or prescribe the app to patients. The World
Health Organization (WHO) defines a ‘medical device’ as
any device, including software, intended by the developer
to be used, in isolation or in combination, for a range of spe-
cific medical purposes in humans, including: diagnosis,
prevention, monitoring, treatment or alleviation of disease
[16]. This definition is sufficiently broad and opaque that it
incorporates the spectrum of addictive behaviour apps.
App developers can seek more nuanced categorization
guidance from their country’s own regulatory agency. To
help readers navigate this complex and confusing land-
scape, we have compared the criteria, features and key
characteristics of addictive behaviour apps that would class
as a medical device according to: (1) the Food and Drug
Administration (FDA, USA) [17], (2) the Medicines and
Healthcare products Regulatory Agency (MHRA, UK)
[18], 3) the Therapeutic Goods Administration (TDA,
Australia), (4) Health Canada and (5) the European Medi-
cines Agency (EMA). For comparative purposes, we have
broadly categorized addictive behaviour apps into three
categories: (1) health and wellbeing apps (or self-help
apps)—designed to help people change an addictive behav-
iour to improve their own health and wellbeing without
any person-orientated support, (2) blended support apps
—combine self-help components with person-orientated
support, which could range from help navigating an app
to the delivery of therapeutic support, for people without
a diagnosed substance use disorder or not receiving formal
clinical therapy and (3) clinical therapy apps—designed as
an adjunct to formal dependence treatment for people with
a substance use disorder. We acknowledge that addictive
behaviour apps do not fall neatly into each of these catego-
ries and, as with in-person intervention approaches, they
constitute a continuum.
All regulatory agencies agree that health and wellbeing
apps used as self-help resources as we have defined them
are not considered medical devices, providing they do not
claim to directly prevent ill health. Blended apps are not ex-
plicitly mentioned in regulatory guidance, although prom-
ising effectiveness data to support a blended approach will
potentially influence future guidance [19,20]. Clinical
therapy apps, often referred to as digital therapeutics, are
less clear cut. FDA and MHRA classify these as medical de-
vices, EMA would consider these as medical devices if the
app creates a ‘hazardous situation’ (see Table 1), whereas
Health Canada does not consider therapeutic apps as med-
ical devices and TDA guidance is unclear. To the best of our
knowledge, only one addictive behaviour app has been for-
mally classified as a medical device. In 2018, the FDA an-
nounced approval of its first and only mHealth app,
reSET, to treat substance use disorders [21]. reSET provides
cognitive behavioural therapy, in combinationwith contin-
gency management, for patients currently enrolled in out-
patient treatment under the supervision of a clinician, and
is available on prescription in the United States. There has
been some criticism of the evidence that supports the reSET
app; namely, that the app has only been found to be effica-
cious in combination with contingency management, an
evidence-based implementation strategy [14], and the ef-
fects of the app alone are not known. Further, the FDA ap-
proval relies upon efficacy evidence; there are no
pragmatic/Phase III effectiveness trials to support its use,
therefore it may not be effective in real-world settings.
Recent innovation in regulatory processes
In 2017, the FDA launched a new approach to app regula-
tion that focuses primarily upon the credibility of the devel-
oper. The FDA pre-certification programme approves
developers with a credible reputation for software develop-
ment [22]. Apps developed by pre-certified developers are
automatically FDA-approved, without the standard review
process. This innovative approach to app regulation is
thought to speed up the availability of apps and thus the
benefit to patients, health professionals and developers. Ef-
forts to address the complex regulatory criteria for apps are
slowly emerging, but cross-country consensus on quality
standards is needed; apps are global products, and there-
fore need international standardization [23,24]. While
therapeutic appsmay benefit some patients with substance
use disorders, the majority of apps for addictive behaviours
are classified as health and wellbeing apps. The FDA has
been criticized for not regulating health and wellbeing
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Table 1 Regulatory guidance and application to addictive behaviour applications (apps).
Regulator
Relevant part of definition for
apps as medical devices Addictive behaviour apps
Health and wellbeing (self-













support (e.g. NHS Drink
Free Days)
An app that combines
support beyond early
intervention, such as
connection to facilitators or
health professionals, with
self-help support (e.g. NIH
sober grid, nomo sobriety
clocks)
A therapeutic app designed












appliance, material or other
article, whether used alone
or in combination, together
with any software
necessary for its proper
application which is
intended by the
manufacturer to be used for
human beings for the
purpose of diagnosis,
prevention, monitoring,
treatment or alleviation of
disease’ [18]
Would only be classed as a
medical device if the app
provides an indication of
future risk, e.g. ‘people with
the same risk factors as you
have anX% chance of heart
disease or claims the app
would directly reduce the
risk of disease
Would only be classed as a
medical device if the app
provides an indication of
future risk, e.g. ‘people with
the same risk factors as you
have anX%chance of heart
disease’ or claims the app
would directly reduce the
risk of disease
‘Apps intended to automate
the treatment pathway for






‘Many mobile apps are
simply sources of
information, or tools to
manage a healthy lifestyle.
The TGA does not regulate
health and lifestyle apps
and software that do not
meet the definition of a
medical device’ [43]




‘When the intended use of a
mobile app is for the
diagnosis of disease or other
conditions, or the cure,
mitigation, treatment, or
prevention of disease, or is
intended to affect the
structure or any function of
the body of man, the mobile
app is a device’…’We intend
to apply this oversight
authority only to those
software applications
whose functionality could
pose a risk to a patient’s
safety if the software
applications were to not
function as intended’ [44]
Not a medical device Not a medical device A medical device
(Continues)
mHealth apps for addictive behaviours 3
© 2021 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
apps. It is argued that they have an ethical duty to prevent
harm to the public, a duty that precariously lies with the
developers and the app stores [25].
Germany has recently adopted a Digital Healthcare Act
(Digitale-Versorgung-Gesetz; DVG), which entitles recipi-
ents of state-funded health insurance to apps classified as
lower-riskmedical devices [26]. These are devices that sup-
port monitoring, detection, relief or treatment of illnesses.
A register of eligible apps has been developed which meet
criteria on safety, functionality, quality, data protection,
data security and positive effects on care (demonstrated
by expert opinion through to experimental studies). How-
ever, the scope of eligible apps is currently limited. Health
and wellbeing apps and potentially blended support apps
are excluded, as they are not considered medical devices
by the EMA (Medical Device Regulation [27]). On one
hand, this approach is a step forward in providing wide-
spread access to effective apps with transparent assessment
procedures, but on the other hand it might restrict access
to or devalue apps that have not or do not need to be clas-
sified as medical devices.
We nowconsider the use of accreditation as an alterna-
tive to regulation for health and wellbeing and blended
support apps for determining quality, safety and
effectiveness.
Accreditation of apps
Whilemany countries are developing robust procedures for
regulating digital health technologies, there is less progress
in providing accreditation and access to these technologies
for patients/consumers or health professionals via curated
on-line libraries or ‘portals’. A lack of formal accreditation
or recommendation of addictive behaviour apps could have
implications for supporting behaviour change. Most apps
are discovered through commercial app store searches
[3,28]. The order in which apps are presented after
searching a commercial app store (‘display rank’) strongly
influences which apps are selected, with people rarely go-
ing beyond the first few apps in search results, as found
with general search engines. Display rank is determined
by uptake (downloads, rate of downloads over time) and
popularity (ratings). Evidence from the uptake of alcohol
and smoking cessation apps on app stores find that app rat-
ings and rankings are only weakly associated with assessed
clinical quality and use of behaviour change techniques
[29,30]. Top-ranking addiction-orientated apps of low clin-
ical quality will, therefore, probably remain top-ranking
apps and impede people motivated to change their addic-
tive behaviour from installing those apps that are more
likely to be clinically effective. This is due in part to the
Table 1. (Continued)
Regulator
Relevant part of definition for
apps as medical devices Addictive behaviour apps




lifestyle, such as general
wellness apps… Software
that is only intended to
support a health care




diagnosis, or treatment of a
disease or condition’ [45]




The EMA has yet to issue
regulation procedure. A
second draft of guidelines
on assessment of the
reliability of mobile health
applications was published
in 2016 [46]
Not a medical device Not a medical device ‘Where “health apps” may
create a hazardous
situation, they are treated
—in terms of development
scrutiny, documentation,
verification and validation
for instance, in a similar
manner to medical devices’
[46]
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dominant entrepreneurial model of app development that
applies ‘agile development’ principles, where apps are de-
veloped and made available early with the intention to en-
hance them continuously based on user feedback,
supported by their income stream [29]. However, most
apps are developed by those outside the health and
addiction field and so lack access to expertise to develop
their evidence-base. Furthermore, often due to financial
pressures, they are not enhanced much after their launch.
Other approaches that can be used by consumers to
identify apps for addictive behaviours, instead of commer-
cial app stores, are slowly growing in number. Curated
on-line app libraries are one such approach. These services,
usually websites, can provide information to users, health
professionals and potentially commissioners to help identify
apps that serve a specific purpose. In some cases, these app
libraries provide a form of accreditation, such as only in-
cluding apps that adhere to thresholds for characteristics
such as quality, user satisfaction or effectiveness. In
England, for example, the second launch of the NHS apps
library in 2017 requires app developers to adhere to speci-
fied criteria to ensure quality. These criteria include some
evidence of effectiveness, as defined by the National
Institute for Health and Care Excellence (NICE) Evidence
Standards Framework [31], regulatory approval obtained
if necessary, demonstration of clinical safety, adherence to
legal and security standards for data privacy, adherence
to theWeb Content Accessibility Guidelines and a commit-
ment to ensure technical stability over the app’s life-time,
although this is soon to be replaced by the Digital Technol-
ogy Assessment Criteria (DTAC). Other examples include
the Alberta Health Services Addiction and Mental Health
Mobile Application Directory [32], which includes apps
with ‘supporting evidence’ such as research articles or pos-
itive expert reviews, although they also include apps from a
‘known reliable source’without supporting evidence. Com-
petitive industry app libraries are more varied in the infor-
mation provided on their criteria for inclusion. Libraries
such as AppScript and ORCHA provide no clear informa-
tion on inclusion criteria or scoring and others, such as
MyHealthApps, refer to recommendations from consumers
and health-care communities and the provision of app in-
formation by the developer on aspects such as contact de-
tails, app pricing, funding source and involvement of
medical advisers for listing an app. As with regulatory pro-
cedures, we need closer international agreement on the
level of evidence required for accreditation.Where the level
of evidence differs across countries there should be strong
justification. In turn, we need greater investment in evalu-
ations of addictive behaviour apps. Further, evidence on
the opportunity cost of using an ineffective or poor clinical
quality app compared with effective apps or other thera-
peutic approaches and subsequent health benefits should
be required for regulation and accreditation [33].
With the vast majority of apps for addictive behaviours
not classified as medical devices, and accreditation not
compulsory, there are ethical concerns over their use.
Capon et al. [34] conducted a review of apps for addictive
behaviours used in research studies and identified ethical
concerns around data storage and transfer, data owner-
ship, third-party access, user anonymity, informed consent,
equality of access, communication of clinically relevant re-
sults, evidence of safety and effectiveness and regulation.
Data protection was found to be the greatest ethical con-
cern with apps for addictive behaviours which target sensi-
tive and possibly illicit behaviours, such as drug use. This
concern is not unfounded. In 2013–14, Huckvale et al.
conducted a cross-sectional assessment of 79 health and
wellbeing apps on the NHS apps library. They found that
two-thirds of apps did not encrypt identifying information
sent over the internet, some apps lacked privacy policies
and most did not describe the nature of personal informa-
tion included in transmissions. Furthermore, four apps
transmitted both identifying and health information with-
out encryption [35]. The NHS apps library has since been
revamped, with these data protection failures addressed,
but this illustrates the complexity of accrediting apps and
the real and potentially incriminating risks faced by their
users, where law enforcement agencies can subpoena data
on illegal drug use in most countries [36]. Accreditation
bodies, as with federal agencies, have an ethical duty to en-
sure technical safeguards are in place to prevent data pro-
tection breaches and build confidence in the security of
personal data.
Pitfalls with public body endorsement
In addition to the NHS apps library in the England, Public
Health England (PHE) offer their own suite of apps to pro-
mote healthy behaviours, which include SmokeFree and
Drink Free Days for smoking cessation and reducing alco-
hol intake, respectively. A challenge for public bodies such
as PHE is that they are expected to provide support tools
prior to demonstrating any evidence of effectiveness, as is
the case with the SmokeFree and Drink Free Days apps.
However, these apps are widely publicized over multi-
media channels, they have inherent credibility for being de-
livered by PHE and, as such, they are likely to be endorsed
by health professionals. We believe this sets a potentially
worrying precedent that a public body, such as PHE, can
develop and disseminate an unevaluated intervention,
which does not meet the criteria to be included in the
NHS apps library.
A current limitation with most existing curated app li-
braries is that there are only a limited number or no apps
available at all to specifically address addictive behaviours.
A partial exception is the Alberta Health Services Addic-
tion and Mental Health Mobile Application Directory. This
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includes eight apps focused on alcohol behaviour change
(two with some connected research but not effectiveness
evidence; six with expert review only), two smoking cessa-
tion apps (both with some evidence of effectiveness) and
four focused on opioid misuse (one with some connected
research but not effectiveness evidence; twowith expert re-
view; one developed by a ‘known reliable source’). The
NHS apps library has no apps that primarily aim to change
addictive behaviours. Public Health England have a cu-
rated library with one smoking cessation and one alcohol
reduction app although, as mentioned above, neither have
evidence of effectiveness. MyHealthApps includes four
smoking cessation (one with evidence of effectiveness; un-
clear if the other three have evidence of effectiveness) and
two alcohol reduction apps (unclear if there is evidence of
effectiveness). AppScript include no addictive behaviour
apps. While accreditation by public bodies is needed for
health and wellbeing and blended support apps for addic-
tive behaviours, their availability is lacking. Another
limitation with apps listed on app libraries is that most
are only available for a single operating system (i.e. iOS or
Android) [37], reducing access further.
The lack of available addictive behaviour apps on cur-
rent curated app libraries is, in part, a symptom of accred-
itation. App developers or owners may not meet all
requirements of an accreditation or assessment process,
or if they do they may not see the value in doing so or have
the knowledge or resources to do so. Most addictive behav-
iour apps also lack research evidence to support their use
and there is a more general issue that most of the apps that
have been evaluated are not available in app stores [6]. For
health apps as a whole, curated app libraries and
third-party websites are estimated to account for between
17 and 21% of health app discoveries [3,28], although
more up-to-date studies are needed. The extent to which
this is true for addictive behaviour apps is unknown. Pro-
viding a greater choice of addictive behaviour apps may
be an important factor for increasing uptake on such plat-
forms, with evidence that people looking for addiction-re-
lated apps have varied preferences based on the look,
description and available features of the app [38]. Given
the large number of addictive behaviour apps found on
app stores, relative to curated app libraries, it is of no sur-
prise that the identification of apps is predominantly di-
rectly through these services. For example, reviews
searching for smoking cessation apps found 400 relevant
apps [39], and 91 alcohol reduction apps in the first 800
alcohol-related apps identified [30], although there are still
few apps focused on managing use of opioids or other sub-
stances [10].
Putting aside the current limited choice of addictive be-
haviour apps, there are benefits to curated app libraries
that include accreditation. A European Union-wide study
reported that having a health-care system evaluate the
quality of an app would encourage 15% of adults to use
health apps more often [40]. Such quality evaluation
would probably circumvent some of the current barriers
to app uptake, such as accuracy and data privacy con-
cerns. A further benefit would be the potential for practi-
tioners in health-care and community settings to
promote use of the app library to increase the absolute up-
take of evidence-based apps among the public, where trust
in the practitioners was high. Unlike app stores’ current ap-
proach, curated app libraries can provide systematic de-
scriptions of app features, user guidance and provide
uptake recommendations, all of which are associated with
app uptake [41]. We hope that, in time, curated app librar-
ies will become the starting-point for users and health pro-
fessionals in the search for suitable apps, rather than the
app stores.
IMPLICATIONS
Apps are complementary to other digital treatment ap-
proaches. Computerized CBT is a long-established evi-
dence-based treatment approach in mental health, which
is routinely delivered for addictive behaviours in many
health-care systems, such as in Sweden and the
Netherlands. A platform of multi-modal evidence-based
technologies should be available to patients and the public,
without sole reliance upon apps. It is important to recog-
nize the speed at which digital technology becomes obso-
lete. Just as we begin to establish an evidence-base for
apps, the popularity of wearables and other sensory devices
is gaining pace. For patients and the public who wish to
track more than one health behaviour, having multiple
apps can be burdensome and users primarily focused on
improving other health behaviours, such as physical activ-
ity, may be deterred from also downloading an addictive be-
haviour app. Apps intended to integrate with existing
health services must consider other health service priori-
ties, such as efforts to link primary, secondary and tertiary
care data sources and beyond, such as criminal justice and
social service databases.
This opinion piece has focused upon regulated and
accredited apps, but with few addictive behaviour apps
available as either medical devices or accredited by
national bodies, researchers, health professionals and
patients/public can assess their quality using a range of dif-
ferent quality rating systems [33,42]. For app developers
and researchers who do wish to gain regulatory approval
and accreditation for their apps, in the United States they
may benefit from partnering with FDA-approved devel-
opers to accelerate the creation and regulation of thera-
peutic apps. In the United Kingdom, Academic Health
Science Networks (AHSNs), a partnership between the
NHS, academia and the private sector, facilitate the way
the NHS identifies, develops and adopts new technologies.
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Digital Health London was born from the South London
AHSN (Health Innovation Network) and was established
specifically to help developers navigate the complex regula-
tory landscape. Further, app developers and researchers
are encouraged to produce pragmatic evidence to demon-
strate the impact of their app in real-world settings.
CONCLUSION
The popularity of apps will undoubtedly continue to accel-
erate, due to the rapid adoption of digital health technolo-
gies, which has been further catalysed by the COVID-19
pandemic. International regulation of apps as medical de-
vices is slowly evolving to address the need for high quality,
safe and effective apps, although criteria vary across coun-
tries and would benefit from standardization in a simple,
usable and transparent format. Efforts to provide accredita-
tion of non-medical device apps are variable and public
bodies provide mixed messages around endorsement. App
developers and researchers are encouraged to work more
closely with pre-certified developers or local Academic
Health Science Networks, who have a good grasp of this
complex regulatory landscape. Health professionals and
patients are encouraged to use accredited apps for addictive
behaviours, where they exist, or explore other forms of dig-
ital intervention with a stronger evidence-base, although
they will need help to do this until there are appropriate fa-
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